Pharmaceutical News

RSS

Emergent BioSolutions signs contract with NIAID to develop third generation anthrax vaccine candidate

Emergent BioSolutions Inc. announced today that it has signed a contract valued at up to $28.7 million with the National Institute of Allergy and Infectious Diseases, an institute within the National Institutes of Health, for advanced development of the company's third generation anthrax vaccine candidate.

2 Sep 2010

AHF proposes innovative solution to resolve AIDS drug crisis in Florida

As the State of Florida grapples with a budget shortfall that is crippling its AIDS Drug Assistance Program and forcing the state to place more than 1,300 low-income Floridians on waiting lists to access lifesaving AIDS medications, AIDS Healthcare Foundation has proposed an innovative solution to state health officials and seven leading AIDS drug companies that would create a public/private partnership to resolve the drug crisis and get vulnerable Florida AIDS patients on to lifesaving antiretroviral treatment.

2 Sep 2010

Dietary supplement combining zinc, phytase enhances effectiveness of BTX injections: Study

Taking a dietary supplement of organic zinc and the enzyme phytase four days before receiving botulinum toxin injections made the toxin more effective in 93 percent of patients tested in a recent study at The Methodist Hospital in Houston.

2 Sep 2010

Lilly's Evista method patents upheld through March of 2014

Eli Lilly and Company today announced that the U.S. Court of Appeals for the Federal Circuit has affirmed a prior ruling by the U.S. District Court for the Southern District of Indiana that the company's method-of-use patents for Evista® (raloxifene HCl tablets) are valid. These patents provide protection for Evista in the U.S. through March of 2014.

2 Sep 2010

Researchers develop new technique to trace counterfeit drugs

Counterfeiting of drugs is a huge industry with an annual turnover of more than SEK 500 billion. In Africa the situation is extremely serious. Half of the malaria medication sold there could be ineffective or even harmful. Researchers from Lund and the UK have now developed a technique that could resolve the situation.

2 Sep 2010

Orexigen and Takeda partner to develop, commercialize Contrave in US, Canada and Mexico

Orexigen® Therapeutics, Inc. and Takeda Pharmaceutical Company Limited, today announced that they have entered into an exclusive partnership to develop and commercialize Contrave® (naltrexone SR/bupropion SR), Orexigen's investigational drug for the treatment of obesity, in the United States, Canada and Mexico.

2 Sep 2010

XARELTO achieves net clinical benefit in treatment of patients with DVT

Bayer HealthCare Pharmaceuticals today announced that XARELTO (rivaroxaban), a novel anti-clotting therapy, achieved improvement in net clinical benefit in a study looking at treatment of patients with deep vein thrombosis. DVT is the formation of a blood clot in a deep vein, usually in the legs, that partially or totally blocks the flow of blood.

2 Sep 2010

BRINAVESS IV granted marketing approval in EU for conversion of recent onset AF to sinus rhythm

MSD and Cardiome Pharma Corp. today announced that the intravenous (IV) formulation of BRINAVESS™ (vernakalant) has been granted marketing approval in the European Union (EU), Iceland and Norway for the conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults.

2 Sep 2010

Biodel replaces Linjeta with trade name VIAject

Biodel Inc. announced today that Linjeta™ (pronounced lin-JET-uh) will replace VIAject as the proposed trade name for Biodel's most advanced product candidate.

2 Sep 2010

QRxPharma announces interim analysis of MoxDuo IR clinical program

QRxPharma announced today a successful interim analysis of its final MoxDuo IR pivotal Phase 3 study required for New Drug Application (NDA) submission.

2 Sep 2010

Nabi Biopharmaceuticals, Diosynth sign long-term commercial manufacturing agreement

Nabi Biopharmaceuticals announced today that it has entered into a long-term commercial manufacturing agreement with Diosynth RTP, Inc. for the manufacture of Drug Substance integral to the production of NicVAX, Nabi's innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse.

2 Sep 2010

Unitract Tuberculin syringe clears FDA 510k market clearance

Unilife Corporation, today announced that its Unitract Tuberculin (TB) Syringe has received 510(k) market clearance from the U.S. Food and Drug Administration (FDA).

2 Sep 2010

Involving pharmacists in direct patient care activities has favorable effects: Study

Incorporating pharmacists as members of the health care team in direct patient care roles is a viable solution to help improve U.S. health care, according to the results of a comprehensive, systematic review of the health care literature set to be published in the October 2010 edition of Medical Care.

2 Sep 2010

FDA approves Atomoxetine HCl capsules for ADHD

Actavis has received approval from the U.S. Food & Drug Administration to market Atomoxetine HCl capsules for the treatment of attention deficit/hyperactivity disorder (ADHD).

2 Sep 2010

Pharmacor 2010 findings predict COPD drug market rise to $13 billion in 2019

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, through 2019, an expanding aging population and increases in diagnosis and drug treatment will fuel steady 4.6 percent annual growth in the chronic obstructive pulmonary disease (COPD) drug market.

2 Sep 2010

USFDA grants Sun Pharma subsidiary approval for generic Strattera capsules ANDA

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Strattera ®, atomoxetine hydrochloride capsules.

2 Sep 2010

FDA approves LUMIGAN eye drops for intraocular pressure reduction in open-angle glaucoma patients

Allergan, Inc. today announced the United States Food and Drug Administration (FDA) has approved LUMIGAN (bimatoprost ophthalmic solution) 0.01% as a first-line therapy indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

2 Sep 2010

Event Pulse report reveals impact of new therapies on MS drug market

The study titled Event Pulse Preview: Multiple Sclerosis shows that 84% of neurologists expect to prescribe Gilenia for some MS patients if approved, but prescribing will likely be limited to second- or third-line therapy until concerns about safety and monitoring requirements are resolved.

1 Sep 2010

Report finds some donated malaria drugs are being stolen, resold In Africa

Some of the malaria drugs given to Africa by international donors are "being stolen and resold on commercial markets," according to a study to be released Thursday in the journal Research and Reports in Tropical Medicine, the Associated Press reports.

1 Sep 2010

Unpleasant short term side-effects of sunburn dont put off sun-seeking Brits

The research - commissioned by Superdrug and Cancer Research UK as part of their joint campaign to encourage people to enjoy the sun safely this summer - highlights the worrying lengths sun-seeking Brits are prepared to go to in search of a tan.

31 Aug 2010

Pharmaceutical News

Emergent BioSolutions signs contract with NIAID to develop third generation anthrax vaccine candidate

AHF proposes innovative solution to resolve AIDS drug crisis in Florida

Dietary supplement combining zinc, phytase enhances effectiveness of BTX injections: Study

Lilly's Evista method patents upheld through March of 2014

Researchers develop new technique to trace counterfeit drugs

Orexigen and Takeda partner to develop, commercialize Contrave in US, Canada and Mexico

XARELTO achieves net clinical benefit in treatment of patients with DVT

BRINAVESS IV granted marketing approval in EU for conversion of recent onset AF to sinus rhythm

Biodel replaces Linjeta with trade name VIAject

QRxPharma announces interim analysis of MoxDuo IR clinical program

Nabi Biopharmaceuticals, Diosynth sign long-term commercial manufacturing agreement

Unitract Tuberculin syringe clears FDA 510k market clearance

Involving pharmacists in direct patient care activities has favorable effects: Study

FDA approves Atomoxetine HCl capsules for ADHD

Pharmacor 2010 findings predict COPD drug market rise to $13 billion in 2019

USFDA grants Sun Pharma subsidiary approval for generic Strattera capsules ANDA

FDA approves LUMIGAN eye drops for intraocular pressure reduction in open-angle glaucoma patients

Event Pulse report reveals impact of new therapies on MS drug market

Report finds some donated malaria drugs are being stolen, resold In Africa

Unpleasant short term side-effects of sunburn dont put off sun-seeking Brits

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Latest News